Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative chemotherapy plus QL1706 in high-risk triple-negative breast cancer
ChiCTR2600121774Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in triple-negative breast cancer (TNBC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 3-year disease-free survival rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600121774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121774.